Time Restricted Eating During Chemotherapy for Breast Cancer

Status Recruiting

Clinical Trial Summary

Breast cancer is the most common cancer in the United States however, little is known about how diet can affect cancer treatment. Pre-clinical murine studies report intermittent fasting increases effectiveness of chemotherapy and decreases treatment related adverse events. The proposed research will demonstrate that time restricted eating, a form of intermittent fasting, will improve treatment related outcomes, patient related outcomes, and limit treatment related weight gain and fat mass accretion.Time restricted eating combined with a mediterranean diet will also be feasible and improve cardiometabolic risk more than TRE alone or standard care.

Clinical Trial Description

Current standard of care during chemotherapy for breast cancer suggests enough daily calories and protein to maintain body weight and avoid muscle loss. However, this approach may be antiquated given weight gain is common during treatment and emerging pre-clinical and clinical evidence suggest that fasting during chemotherapy may improve clinical and patient-reported outcomes. For example, preliminary human trials examining the fasting mimicking diet (very low-calorie, low-protein diet 1-week per month) or short term fasting (48-120 hours (h)), known as periodic fasting, surrounding chemotherapy may increase effectiveness of treatment and decrease side effects related to chemotherapy. Yet these diets have low adherence, side effects of their own, and may increase patient burden and decrease quality of life. In contrast, time restricted eating (TRE) is a form of intermittent fasting with high adherence that may have similar positive effects on treatment outcomes without the untoward side-effects. Moreover, TRE may have beneficial effects on glucose regulation and body composition (i.e., decreased weight and body fat gain) suggesting the potential importance of this regimen to breast cancer recurrence. TRE is extremely accessible with no calorie counting or financial burden to the patient, individuals just shorten their eating window daily. However TRE also does no address diet quality. The Mediterranean diet has also been shown to improve patient and treatment outcomes in this population. The additive effect might be even more beneficial. Despite the potential benefits, TRE alone or TRE combined with a mediterranean has not been investigated in breast cancer patients during chemotherapy treatment. We aim to test the safety and feasibility of 8-h TRE compared to TRE combined with a mediterranean style diet among female breast cancer patients initiating chemotherapy for stage I-III breast cancer. We further strive to examine the preliminary efficacy of TRE or TRE with the mediterranean diet on treatment related outcomes, treatment related side effects, patient-reported quality of life and fatigue, blood-based metabolic markers and body/weight adiposity compared to the current standard of care. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05259410
Study type	Interventional
Source	University of Illinois at Chicago
Contact	Kelsey Gabel, PhD
Phone	312-413-8911
Email	kdipma2@uic.edu
Status	Recruiting
Phase	N/A
Start date	August 1, 2022
Completion date	March 1, 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03080623` - Ultrasound-based Diagnostic Model for Differentiating Malignant Breast Lesion From Benign Lesion
Completed	`NCT05527769` - Pain and Functional Recovery After Mastectomy and IBR by Implant: Prepectoral Versus Subpectoral Technique
Completed	`NCT06376578` - Exercise Interventions for Improving Health in Breast Cancer Survivors	N/A
Completed	`NCT03004534` - A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide	Early Phase 1
Recruiting	`NCT05020574` - Microbiome and Association With Implant Infections	Phase 2
Active, not recruiting	`NCT06277141` - The Vitality Mammography Messaging Study	N/A
Completed	`NCT03555227` - USG PECS vs LIA for Breast Cancer Surgery	N/A
Completed	`NCT03270111` - High Physical Activity During a Weight Loss Intervention for Breast Cancer Survivors and High Risk Women	N/A
Active, not recruiting	`NCT03917082` - Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer	Phase 2
Recruiting	`NCT05561842` - Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries)
Completed	`NCT04554056` - Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF	Phase 2/Phase 3
Active, not recruiting	`NCT03127995` - Hypofractionated vs Standard Radiotherapy in Breast Cancer With an Indication for Regional Lymph Node Irradiation About Lymphedema Occurrence	N/A
Active, not recruiting	`NCT02237469` - Prone Breast Radiotherapy Treatment Planning Observational Study
Completed	`NCT01204125` - Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients	Phase 2
Recruiting	`NCT04565054` - Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC	Phase 3
Not yet recruiting	`NCT06412133` - Conversations in Light and Shadow: Assessing Phototherapy's Impact on Breast Cancer Patients	N/A
Recruiting	`NCT03956641` - Evolution of the Physical Condition in Treated Cancer Patients	N/A
Recruiting	`NCT06087120` - Investigate the Prognostic and Predictive Value of ctDNA During Neoadjuvant Chemotherapy for Breast Cancer.
Recruiting	`NCT06058936` - Exercises Using Virtual Reality on Cancer Patients	N/A
Completed	`NCT03470935` - Non-interventional Study Evaluating Gynecological Impact of Diagnosis and Treatment of Breast Cancer in Patients Younger